CoChat

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42

Open access
Lauridsen, Camilla, Sando, Sigrid B., Møller, Ina, Berge, Guro, Pomary, Precious K., Grøntvedt, Gøril R., Salvesen, Øyvind, Bråthen, Geir, White, Linda R. · 2017 · Frontiers in Aging Neuroscience
Cited by 26

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background Amyloid beta 1-43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s disease (AD). We have investigated cerebrospinal fluid (CSF) levels of Aβ43 in patients with early-onset AD in contrast to levels in late-onset AD. For comparison, in addition to the ‘core’ biomarkers, several other analytes were also determined (YKL-40, neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), and progranulin). Material and Methods CSF samples were obtained from patients with early-onset AD (age≤62, n=66), late-onset AD (age≥68, n=25), and groups of cognitively intact individuals (age≤62, n=41, age≥68, n=39). Core CSF AD biomarkers (amyloid beta 1-42 (Aβ42), total tau, phosphorylated tau) were analyzed, as well as levels of Aβ43 and other analytes, using commercially-available enzyme-linked immunosorbent assays. Results CSF Aβ43 was significantly reduced in early-onset AD compared to late-onset AD (14.8 ± 7.3 vs. 21.8 ± 9.4 pg/ml respectively), whereas the levels of Aβ42 in the two AD groups were not significantly different (474.9 ± 142.0 vs. 539.6 ± 159.9 pg/ml respectively). Aβ43 and all core biomarkers were significantly altered in patients with AD compared to corresponding controls. NF-L was significantly increased in early-onset AD compared to younger controls, an effect not found between the older groups. Relationships between the Aβ peptides and tau proteins, YKL-40, NF-L, GFAP and progranulin were also investigated without finding marked associations. However, age-associated increases in levels of tau proteins, YKL-40, NF-L and GFAP were found with respect to age in healthy controls. Results for these other analytes were similar to previously published data. Aβ43 did not improve diagnostic accuracy in either AD group compared to Aβ42. Discussion CSF Aβ43, but not Aβ42 levels, varied significantly with age in patients with AD. If CSF levels of Aβ peptides reflect amyloid deposition in brain, the possibility arises that there is a difference between Aβ43 and Aβ42 deposition in younger compared to older brain. However, the level of Aβ43 in CSF shows no improvement over Aβ42 regarding diagnostic accuracy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2017.00210

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 26

Metadata

Authors
Lauridsen, C., Sando, S. B., Møller, I., Berge, G., Pomary, P. K., Grøntvedt, G. R., Salvesen, Ø., Bråthen, G., & White, L. R.
Venue
Frontiers in Aging Neuroscience
Published
2017-06-28
Volume
9
Pages
210-210
ISSN
1663-4365 (ISSN-L)
OpenAlex
W2733497613
Cited by
26
References
11
FWCI
1.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42. https://app.cochat.ai/papers/10.3389/fnagi.2017.00210
The paper
Lauridsen, C., Sando, S. B., Møller, I., Berge, G., Pomary, P. K., Grøntvedt, G. R., Salvesen, Ø., Bråthen, G., & White, L. R. (2017). Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2017.00210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.